Marvel Biosciences Corp. (TSXV:MRVL)

Market Cap	8.70M +29.5%
Revenue (ttm)	n/a
Net Income	-2.28M
EPS	-0.05
Shares Out	58.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,500
Average Volume	52,067
Open	0.1450
Previous Close	0.1400
Day's Range	0.1450 - 0.1500
52-Week Range	0.0750 - 0.4000
Beta	0.91
RSI	53.14
Earnings Date	Mar 27, 2026

About Marvel Biosciences

Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program. The company is headquartered in Calgary, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: J. Matheson
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: MRVL